Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
Braatvedt
G D
GD
Department of Medicine, Auckland Hospital.
D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D005907:Gliclazide / Q000009:adverse effects*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*
D001786:Blood Glucose; D006728:Hormones; D007004:Hypoglycemic Agents; D005907:Gliclazide; D015282:Octreotide